NDDS Important Questions Unit-wise (Novel Drug Delivery System, BP704T)

NDDS Important Questions Unit-wise (Novel Drug Delivery System, BP704T)

By Vignesh, Pharma Graduate · Member of LBP · Updated November 2026

Novel Drug Delivery System (NDDS) is full of systems that sound alike: matrix and reservoir, osmotic pumps and implants, liposomes and niosomes. Students lose marks by mixing them up. The way out is to prepare the repeated questions with a fixed answer structure.

Here are the NDDS important questions unit-wise for B.Pharm Semester 7 (BP704T, PCI syllabus). Start with the ★ questions, then read the two sample answers and try the MCQs at the end.

Want every answer written out? The NDDS Exam Pack has model answers for all the ★ questions. Just ₹49. See the pack →

Novel Drug Delivery System exam pattern (BP704T)

SectionQuestionsMarks
I. Objective (MCQs / fill in the blanks / one-word)10 × 2 (or 20 × 1)20
II. Long answersAnswer 2 of 3 × 1020
III. Short answersAnswer 7 of 9 × 535
Total3 hours75

For every delivery system, write: definition → advantages and limitations → types or approaches → formulation components → evaluation, with a labelled diagram.

Novel Drug Delivery System important questions, unit-wise

★ marks the questions asked most often in university papers. Prepare these first.

Unit I: Controlled drug delivery systems and polymers

Long (10 marks)

  • ★ Define controlled drug delivery. Discuss its advantages, disadvantages, the selection of drug candidates, and the physicochemical and biological factors in design.
  • ★ Explain the approaches to the design of controlled release systems (dissolution, diffusion, dissolution–diffusion, osmotic, ion exchange).
  • Define polymers. Classify them and discuss their properties and applications in controlled release.

Short (5 marks)

  • ★ Sustained vs controlled release · Biodegradable polymers (PLGA) · Matrix and reservoir systems · Ion exchange resins

Unit II: Microencapsulation, mucoadhesion, implants

Long

  • ★ Define microencapsulation. Discuss the methods of preparation of microcapsules and microspheres (coacervation, spray drying, solvent evaporation, air suspension, pan coating) and their evaluation.
  • ★ Define mucoadhesion. Explain the theories, factors affecting mucoadhesion, and buccal drug delivery.

Short

  • ★ Microspheres vs microcapsules · Mucoadhesive polymers · Implantable drug delivery systems · Osmotic pumps (OROS, Alzet)

Unit III: Transdermal, gastroretentive, nasopulmonary

Long

  • ★ Describe the transdermal drug delivery system: skin structure, permeation pathways, factors, components (polymer matrix, drug, enhancers, adhesive, backing, liner), types of TDDS and evaluation.
  • ★ Explain the approaches to gastroretentive drug delivery (floating, high-density, swelling, mucoadhesive, raft-forming).

Short

  • ★ Permeation enhancers · Iontophoresis · Floating drug delivery systems · Intranasal drug delivery · Pulmonary delivery: MDI, DPI, nebulisers

Unit IV: Targeted drug delivery

Long

  • ★ Explain the concept of targeted drug delivery (passive, active, physical targeting; first, second and third order). Describe liposomes: classification, preparation, evaluation and applications.

Short

  • ★ Niosomes · Nanoparticles (polymeric, SLN) · Monoclonal antibodies in targeting · EPR effect

Unit V: Ocular and intrauterine drug delivery

Short

  • ★ Ocular drug delivery: barriers, methods to overcome them, ocular inserts (Ocusert), in situ gels
  • ★ Intrauterine devices (IUDs): development, types (inert, copper, hormone-releasing), advantages and disadvantages

NDDS EXAM PACK · B.PHARM SEM 7

All the unit-wise important questions above with 16 model answers in exam format, 46 MCQs with explanations, in one PDF. Instant download. ₹49 ₹99

Get the answers →

Need every Sem 7 subject? The B.Pharm Sem 7 Exam Pack covers all theory papers for ₹99.

Sample model answers

Here are 2 answers written the way examiners like them. The pack has model answers for every ★ question.

Niosomes (5 marks)

Definition: niosomes are non-ionic surfactant vesicles: bilayer vesicles formed from non-ionic surfactants (± cholesterol) in an aqueous medium. They are structurally similar to liposomes but use non-ionic surfactants instead of phospholipids. (First reported for cosmetics by L’Oréal in the 1970s–80s.)

Composition:

  • Non-ionic surfactants: sorbitan esters (Spans: Span 20, 40, 60, 80), polysorbates (Tweens), polyoxyethylene alkyl ethers (Brij), crown ethers, polyglyceryl alkyl ethers.
  • Cholesterol: stabilises the bilayer (increases rigidity, reduces leakage).
  • Charge inducers: dicetyl phosphate (negative) or stearylamine (positive).
  • Hydration medium (buffer).

Methods of preparation: similar to liposomes: thin film hydration (hand shaking), ether injection, reverse-phase evaporation, sonication, membrane extrusion, microfluidisation, the bubble method (no organic solvents), “proniosome” technology (a dry, free-flowing powder of surfactant coated on a carrier (sorbitol, maltodextrin), which forms niosomes on hydration: improves stability).

Niosomes vs liposomes:

LiposomesNiosomes
Made of phospholipidsMade of non-ionic surfactants
Chemically unstable (phospholipids oxidise and hydrolyse)More chemically stable
Expensive (purified phospholipids)Cheaper
Need special storage (cold, inert atmosphere)No special storage or handling needed
Natural lipids: variable puritySurfactants of uniform quality
Both carry hydrophilic and lipophilic drugs; both are biocompatibleSome surfactants may cause irritation or haemolysis

Advantages: osmotically active and stable; improve oral bioavailability of poorly absorbed drugs; increase skin penetration (topical delivery); targeting (RES uptake, tumours); sustained release; and low cost.

Applications:

  • Anticancer drugs (methotrexate, doxorubicin: altered distribution, less toxicity).
  • Leishmaniasis (sodium stibogluconate niosomes: higher liver and spleen levels).
  • Topical and transdermal delivery (e.g. NSAIDs, antifungals, minoxidil, cosmetics: L’Oréal’s anti-ageing creams (Lancôme Niosome)).
  • Ophthalmic delivery (e.g. timolol, acetazolamide).
  • Vaccine adjuvants and peptide delivery (oral insulin trials), diagnostic imaging (contrast agents).
  • Evaluation: as for liposomes (size, zeta potential, entrapment efficiency, in vitro release, morphology, stability).

Targeted drug delivery: concepts (5 marks)

Definition: targeted (site-specific) drug delivery is the selective delivery of a drug to its site of action (target organ, tissue or cell) in such a way that the drug reaches its target while minimising exposure to non-target sites. The concept of the “magic bullet” was put forward by Paul Ehrlich (1906).

Advantages:

  • Higher drug concentration at the target and better efficacy.
  • Lower dose required.
  • Fewer side effects and lower toxicity (especially for anticancer drugs).
  • Protection of the drug from degradation; prolonged circulation.
  • Possible delivery of genes, proteins and peptides.
  • Reduced fluctuations in drug levels.

Disadvantages: rapid clearance of carriers by the RES (reticuloendothelial system: liver, spleen; macrophages); immune reactions; difficulty crossing biological barriers; complex manufacture, high cost, stability problems, limited drug loading, and the need for skilled handling.

Levels of targeting:

  • First-order targeting: to a specific organ or tissue (e.g. compartment targeting: intraperitoneal, intra-articular, intrathecal, lymphatic, the lungs).
  • Second-order targeting: to specific cells within a tissue (e.g. tumour cells, Kupffer cells of the liver).
  • Third-order targeting: to specific intracellular sites (e.g. lysosomes (endocytosis), the nucleus (gene delivery), mitochondria).

Approaches to targeting:

  1. Passive targeting: uses the natural distribution of carriers in the body according to their physicochemical properties (size, surface charge, hydrophobicity).
    • RES uptake: carriers (> 100 nm) are taken up by macrophages of the liver and spleen (useful for liver diseases, leishmaniasis, fungal infections: e.g. liposomal amphotericin B (AmBisome)).
    • Enhanced permeability and retention (EPR) effect (Matsumura and Maeda, 1986): tumour blood vessels are leaky (with gaps of 100–800 nm) and tumours have poor lymphatic drainage, so nanocarriers (10–200 nm) accumulate and are retained in tumours (e.g. Doxil: PEGylated liposomal doxorubicin).
    • Size-based filtering: microparticles (7–12 µm) are trapped in the lung capillaries after IV injection.
  2. Inverse targeting: blocking the RES (e.g. with blank carriers or dextran sulphate) to avoid uptake of carriers by the RES, so they reach other sites.
  3. Active targeting: carriers are modified with ligands that bind specifically to receptors or antigens on target cells:
    • Antibodies and antibody fragments (immunoliposomes; antibody–drug conjugates, e.g. trastuzumab emtansine (Kadcyla)).
    • Folic acid (folate receptors are over-expressed on many cancer cells), transferrin (transferrin receptors: brain, tumours), peptides (RGD: integrins), aptamers, galactose (asialoglycoprotein receptors on hepatocytes), mannose (macrophages).
    • Stealth (long-circulating) carriers: PEGylation (coating with polyethylene glycol) reduces opsonisation and RES uptake, prolonging circulation.
  4. Physical targeting: the carrier responds to an external stimulus at the target site:
    • Magnetic (magnetic microspheres guided by an external magnet).
    • Temperature (thermosensitive liposomes with local hyperthermia).
    • pH (pH-sensitive carriers release the drug in the acidic tumour or endosomal environment).
    • Ultrasound, light (photodynamic therapy), and electric fields.
  5. Dual and double targeting: a combination of approaches (e.g. carrier + prodrug, temporal and spatial targeting).

Carriers for targeted delivery:

  • Particulate: liposomes, niosomes, nanoparticles (polymeric, SLN, NLC, gold, magnetic), microspheres, dendrimers, polymeric micelles, nanoemulsions, resealed erythrocytes, virosomes, pharmacosomes, ethosomes (skin), transferosomes (skin).
  • Soluble / macromolecular: monoclonal antibodies, polymer–drug conjugates, albumin (Abraxane), lectins.
  • Cellular: erythrocytes, leucocytes, platelets, stem cells.

5 practice MCQs with answers

1. A system that maintains a constant (zero-order) drug release rate for a predetermined period is a:

  • a) Repeat action system
  • b) Sustained release system
  • c) Controlled release system
  • d) Delayed release system
Show answer

Answer: c. Sustained release prolongs action but without precise rate control.

2. A drug most suitable for an oral controlled release formulation has a half-life of:

  • a) Any half-life
  • b) Less than 1 hour
  • c) 2–8 hours
  • d) More than 24 hours
Show answer

Answer: c. Very short or very long half-lives are unsuitable.

3. Sudden release of a large part of the drug from a controlled release dosage form is called:

  • a) Burst effect only
  • b) Dose dumping
  • c) Lag time
  • d) Tailing
Show answer

Answer: b. It can occur if the membrane ruptures or with alcohol.

4. Release from a matrix diffusion system follows the:

  • a) Henderson–Hasselbalch equation
  • b) Noyes–Whitney equation
  • c) Higuchi equation (Q ∝ √t)
  • d) Arrhenius equation
Show answer

Answer: c. The rate falls as the diffusion path lengthens.

5. In the Korsmeyer–Peppas model, an n value of 0.89 (for cylinders) indicates:

  • a) Anomalous transport
  • b) Case II transport (zero order)
  • c) First-order release
  • d) Fickian diffusion
Show answer

Answer: b. n = 0.45 indicates Fickian diffusion.

Free NDDS notes, unit-wise

Related guides

Frequently asked questions

Which units are most important in NDDS?

Unit I (controlled release concepts and polymers), Unit III (transdermal and gastroretentive systems) and Unit IV (targeted delivery, liposomes) give most of the long answers.

What is the difference between liposomes and niosomes?

Liposomes are vesicles made of phospholipids; niosomes are made of non-ionic surfactants with cholesterol. Niosomes are cheaper and more chemically stable.

How do I remember the evaluation tests in NDDS?

Group them: physical (size, shape, thickness), drug content and entrapment, in-vitro release, and stability. The same groups work for most systems.

Is NDDS the same as BP704T?

Yes. In the PCI B.Pharm syllabus, Novel Drug Delivery System is the Semester 7 theory paper BP704T.

NDDS EXAM PACK · B.PHARM SEM 7

All the unit-wise important questions above with 16 model answers in exam format, 46 MCQs with explanations, in one PDF. Instant download. ₹49 ₹99

Get the answers →

Need every Sem 7 subject? The B.Pharm Sem 7 Exam Pack covers all theory papers for ₹99.

About the Author

You may also like these